Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
EZH2 inhibitor |
| gptkbp:administeredBy |
preclinical studies
|
| gptkbp:bioactivity |
antitumor activity in EZH2 mutant cancers
|
| gptkbp:CASNumber |
1346574-57-9
|
| gptkbp:criteria |
selective for EZH2 over EZH1
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:hasMolecularFormula |
C21H22N6O2S2
|
| https://www.w3.org/2000/01/rdf-schema#label |
GSK126
|
| gptkbp:inhibitedBy |
H3K27 methylation
|
| gptkbp:IUPACName |
gptkb:(E)-N-((1,3-dimethyl-1H-pyrazol-4-yl)methyl)-2-(4-(pyridin-2-yl)thiazol-2-yl)ethene-1-sulfonamide
|
| gptkbp:mechanismOfAction |
inhibits histone methyltransferase EZH2
|
| gptkbp:molecularWeight |
454.57 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1743088
46224516 |
| gptkbp:synonym |
gptkb:GSK-126
|
| gptkbp:target |
gptkb:EZH2
|
| gptkbp:used_in_research_for |
gptkb:cancer
leukemia epigenetic therapy |
| gptkbp:bfsParent |
gptkb:EZH2
|
| gptkbp:bfsLayer |
7
|